These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 30367145)

  • 81. Anticancer active trifluoromethylated fused triazinones are safe for early-life stages of zebrafish (
    Sztanke M; Rzymowska J; Sztanke K
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):336-344. PubMed ID: 33390035
    [TBL] [Abstract][Full Text] [Related]  

  • 82. A Tumor-in-Host DEB-Based Approach for Modeling Cachexia and Bevacizumab Resistance.
    Tosca EM; Rocchetti M; Pesenti E; Magni P
    Cancer Res; 2020 Feb; 80(4):820-831. PubMed ID: 31818849
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Apatinib induces 3-hydroxybutyric acid production in the liver of mice by peroxisome proliferator-activated receptor α activation to aid its antitumor effect.
    Feng S; Wang H; Wang Y; Sun R; Xie Y; Zhou Z; Wang H; Aa J; Zhou F; Wang G
    Cancer Sci; 2019 Oct; 110(10):3328-3339. PubMed ID: 31429167
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Zebrafish xenografts as a fast screening platform for bevacizumab cancer therapy.
    Rebelo de Almeida C; Mendes RV; Pezzarossa A; Gago J; Carvalho C; Alves A; Nunes V; Brito MJ; Cardoso MJ; Ribeiro J; Cardoso F; Ferreira MG; Fior R
    Commun Biol; 2020 Jun; 3(1):299. PubMed ID: 32523131
    [TBL] [Abstract][Full Text] [Related]  

  • 85. The way forward: new drugs and new therapeutic strategies in lung cancer therapy.
    Scagliotti GV; Novello S
    Clin Lung Cancer; 2006 May; 7 Suppl 4():S109-10. PubMed ID: 16764756
    [No Abstract]   [Full Text] [Related]  

  • 86. Use of zebrafish to model chemotherapy and targeted therapy gastrointestinal toxicity.
    Van Sebille YZ; Gibson RJ; Wardill HR; Carney TJ; Bowen JM
    Exp Biol Med (Maywood); 2019 Oct; 244(14):1178-1185. PubMed ID: 31184924
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Therapy with antitumor lipids: worming the way.
    Pérez-Martín J
    Cell Cycle; 2014; 13(19):2993. PubMed ID: 25486559
    [No Abstract]   [Full Text] [Related]  

  • 88. Editorial: Angiogenesis blockade for the treatment of gastrointestinal cancer.
    Passardi A; Bittoni A; Bai Z; Zhang Z; Sier C; He Y; Shahini E; Solimando AG
    Front Oncol; 2023; 13():1147849. PubMed ID: 36816979
    [No Abstract]   [Full Text] [Related]  

  • 89. Apatinib for salvage treatment of advanced malignant pleural mesothelioma: A case report.
    Du Z; Yu Y; Wu D; Zhang G; Wang Y; He L; Meng R
    Medicine (Baltimore); 2018 Nov; 97(45):e13105. PubMed ID: 30407323
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Apatinib affect VEGF-mediated cell proliferation, migration, invasion via blocking VEGFR2/RAF/MEK/ERK and PI3K/AKT pathways in cholangiocarcinoma cell.
    Huang M; Huang B; Li G; Zeng S
    BMC Gastroenterol; 2018 Nov; 18(1):169. PubMed ID: 30400838
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Effects of Modulating Actin Dynamics on HER2 Cancer Cell Motility and Metastasis.
    Nersesian S; Williams R; Newsted D; Shah K; Young S; Evans PA; Allingham JS; Craig AW
    Sci Rep; 2018 Nov; 8(1):17243. PubMed ID: 30467396
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Akt1 inhibition promotes breast cancer metastasis through EGFR-mediated β-catenin nuclear accumulation.
    Li W; Hou JZ; Niu J; Xi ZQ; Ma C; Sun H; Wang CJ; Fang D; Li Q; Xie SQ
    Cell Commun Signal; 2018 Nov; 16(1):82. PubMed ID: 30445978
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Targeting Purinergic Receptor P2Y2 Prevents the Growth of Pancreatic Ductal Adenocarcinoma by Inhibiting Cancer Cell Glycolysis.
    Hu LP; Zhang XX; Jiang SH; Tao LY; Li Q; Zhu LL; Yang MW; Huo YM; Jiang YS; Tian GA; Cao XY; Zhang YL; Yang Q; Yang XM; Wang YH; Li J; Xiao GG; Sun YW; Zhang ZG
    Clin Cancer Res; 2019 Feb; 25(4):1318-1330. PubMed ID: 30420446
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Immunological therapy: A novel thriving area for triple-negative breast cancer treatment.
    Wang X; Qi Y; Kong X; Zhai J; Li Y; Song Y; Wang J; Feng X; Fang Y
    Cancer Lett; 2019 Feb; 442():409-428. PubMed ID: 30419345
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer.
    Liu Y; Xu J; Choi HH; Han C; Fang Y; Li Y; Van der Jeught K; Xu H; Zhang L; Frieden M; Wang L; Eyvani H; Sun Y; Zhao G; Zhang Y; Liu S; Wan J; Huang C; Ji G; Lu X; He X; Zhang X
    Nat Commun; 2018 Nov; 9(1):4718. PubMed ID: 30413718
    [TBL] [Abstract][Full Text] [Related]  

  • 96. VEGFR-2 Inhibitor Apatinib Hinders Endothelial Cells Progression Triggered by Irradiated Gastric Cancer Cells-derived Exosomes.
    Li G; Lin H; Tian R; Zhao P; Huang Y; Pang X; Zhao L; Cao B
    J Cancer; 2018; 9(21):4049-4057. PubMed ID: 30410610
    [No Abstract]   [Full Text] [Related]  

  • 97. Fertility preservation with random-start controlled ovarian stimulation and embryo cryopreservation for early pregnancy-associated breast cancer.
    Pereira N; Kligman I; Hunt R; Kopparam R; Wahmann B; Rosenwaks Z
    Gynecol Endocrinol; 2019 Mar; 35(3):214-216. PubMed ID: 30403906
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Menopausal Hormone Therapy use and breast cancer risk by receptor subtypes: Results from the New South Wales Cancer Lifestyle and EvaluAtion of Risk (CLEAR) study.
    Salagame U; Banks E; O'Connell DL; Egger S; Canfell K
    PLoS One; 2018; 13(11):e0205034. PubMed ID: 30403669
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Androgen excess in breast cancer development: implications for prevention and treatment.
    Secreto G; Girombelli A; Krogh V
    Endocr Relat Cancer; 2019 Feb; 26(2):R81-R94. PubMed ID: 30403656
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Exosomes Released from Tumor-Associated Macrophages Transfer miRNAs That Induce a Treg/Th17 Cell Imbalance in Epithelial Ovarian Cancer.
    Zhou J; Li X; Wu X; Zhang T; Zhu Q; Wang X; Wang H; Wang K; Lin Y; Wang X
    Cancer Immunol Res; 2018 Dec; 6(12):1578-1592. PubMed ID: 30396909
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.